Aged Catheterization Female Hospitalization Humans Lasers Solid-State/*therapeutic use Male Middle Aged Muscles/*pathology Neoplasm Recurrence Local/pathology Postoperative Complications/etiology Publication Bias Treatment Outcome Urethral Stricture/surgery Urinary Bladder Neoplasms/pathology/*surgery *Urologic Surgical Procedures Holmium laser Meta-analysis Non-muscle-invasive bladder cancer Transurethral resection

Adjuvants Immunologic/therapeutic use Administration Intravesical Consensus Humans Neoplasm Invasiveness Neoplasm Recurrence Local/drug therapy *Urinary Bladder Neoplasms/drug therapy Bladder neoplasms Expert consensus Intravesical therapy

Administration Intravesical BCG Vaccine/therapeutic use *Carcinoma in Situ/diagnosis/therapy Female Humans Male Neoplasm Invasiveness *Urinary Bladder Neoplasms/diagnosis/pathology/therapy *Urology *BCG unresponsive *Bacillus Calmette-Guerin (BCG) *Bladder cancer *Cystoscopy *Diagnosis *European Association of Urology (EAU) *Follow-up *Guidelines *Intravesical chemotherapy *Prognosis *Radical cystectomy *Transurethral resection (TUR) *Urothelial carcinoma

5-alpha Reductase Inhibitors/therapeutic use Androgen Antagonists/therapeutic use Androgens/therapeutic use *Carcinoma in Situ Humans Male *Prostatic Neoplasms/pathology *Urinary Bladder Neoplasms/pathology *Androgen suppression therapy *Androgens *Bladder cancer *Incidence *Recurrence *Systematic review

Antineoplastic Agents Alkylating/pharmacology/*therapeutic use Cyclophosphamide/pharmacology/*therapeutic use Female Humans Male Survival Analysis Urinary Bladder Neoplasms/*drug therapy/mortality Cyclophosphamide Hematuria Systematic review Urinary bladder neoplasms

*Carcinoma Transitional Cell Evidence-Based Medicine Humans *Radiology Societies Medical United States *Urinary Bladder Neoplasms/diagnostic imaging Auc Appropriate Use Criteria Appropriateness Criteria Bladder cancer Muscle invasive bladder cancer Nonmuscle invasive bladder cancer Surveillance Transitional cell carcinoma Urothelial cancer

Antineoplastic Agents/*therapeutic use Chemotherapy Adjuvant/*statistics & numerical data *Cystectomy Global Health Guideline Adherence/statistics & numerical data Humans Models Statistical Neoadjuvant Therapy/*statistics & numerical data Neoplasm Invasiveness Practice Guidelines as Topic Practice Patterns Physicians'/*statistics & numerical data Urinary Bladder Neoplasms/*drug therapy/pathology/surgery

Antihypertensive Agents/*adverse effects/therapeutic use Disease Susceptibility Dose-Response Relationship Drug Humans Hypertension/complications/drug therapy/etiology Kidney Neoplasms/*epidemiology/*etiology Odds Ratio Publication Bias Risk Assessment Risk Factors Urinary Bladder Neoplasms/*epidemiology/*etiology antihypertensive medications bladder cancer kidney cancer meta-analysis risk interest.

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Chemotherapy Adjuvant *Cystectomy/methods Humans Neoadjuvant Therapy Neoplasm Invasiveness Survival Rate Urinary Bladder Neoplasms/*drug therapy/mortality/pathology/*surgery Muscle-invasive bladder cancer Neoadjuvant chemotherapy Overall survival Radical cystectomy

Androgen Antagonists/*therapeutic use Humans Male Observational Studies as Topic Prostatic Neoplasms/*drug therapy Risk Assessment Urinary Bladder Neoplasms/epidemiology/*prevention & control Androgen deprivation therapy Bladder cancer Pharmacoepidemiology Prostate cancer Systematic review

Anesthetics Local/*therapeutic use *Cystoscopy Humans Lidocaine/*therapeutic use Male Pain Management/*methods Pain Measurement Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/diagnosis/therapy administration cystoscopy intravesical lidocaine pain procedural urinary bladder neoplasms

Antibodies Monoclonal/adverse effects/therapeutic use Antibodies Monoclonal Humanized/adverse effects/therapeutic use Antineoplastic Agents Immunological/*therapeutic use B7-H1 Antigen/*antagonists & inhibitors Clinical Trials Phase III as Topic Humans Network Meta-Analysis Programmed Cell Death 1 Receptor/*antagonists & inhibitors Salvage Therapy/*methods Survival Analysis Treatment Outcome Urinary Bladder Neoplasms/*drug therapy/*secondary PD-1 inhibitor PDL-1 inhibitor atezolizumab pembrolizumab urothelial bladder cancer

Diabetes Mellitus Type 2/complications/drug therapy Humans Hypoglycemic Agents/*adverse effects/therapeutic use Odds Ratio Pioglitazone/*adverse effects/therapeutic use Randomized Controlled Trials as Topic Risk Assessment Risk Factors Time Factors Urinary Bladder Neoplasms/*etiology Bladder cancer dose-response relationship meta-analysis pioglitazone

Cystectomy Humans Procedures and Techniques Utilization/*statistics & numerical data Prospective Studies Retrospective Studies Risk Assessment Urinary Bladder Neoplasms/*surgery Predictors Radical cystectomy Use Utilization interest including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg employment/affiliation grants or funding consultancies honoraria stock ownership or options expert testimony royalties or patents filed received or pending) are the following: None.

Adjuvants Immunologic/*therapeutic use Administration Intravesical BCG Vaccine/*therapeutic use Carcinoma Transitional Cell/pathology/*therapy Cystoscopy Female Humans Male Multivariate Analysis Muscle Smooth/*pathology Neoplasm Invasiveness Neoplasm Recurrence Local/*epidemiology Proportional Hazards Models Sex Factors Survival Rate Urinary Bladder Neoplasms/pathology/*therapy *Urologic Surgical Procedures Bladder cancer Gender differences Local recurrence Meta-analysis Transurethral resection of bladder tumor

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Cisplatin/administration & dosage Deoxycytidine/administration & dosage/analogs & derivatives Doxorubicin/administration & dosage Humans Methotrexate/administration & dosage Muscle Neoplasms/*drug therapy/pathology Neoplasm Invasiveness Prognosis Survival Rate Urinary Bladder Neoplasms/*drug therapy/pathology Vinblastine/administration & dosage Gemcitabine Bladder cancer and cisplatin chemotherapy doxorubicin/adriamycin gemcitabine and cisplatin methotrexate vinblastine

Cisplatin/*therapeutic use Female Humans Male Neoadjuvant Therapy/*methods Urinary Bladder/drug effects/pathology Urinary Bladder Neoplasms/*drug therapy/pathology

Administration Intravesical Aged Aged 80 and over BCG Vaccine/*therapeutic use Biopsy Needle Disease-Free Survival Female Humans Immunohistochemistry Immunotherapy/*methods In Situ Hybridization Fluorescence Male Middle Aged Neoplasm Recurrence Local/mortality/*pathology Predictive Value of Tests Prognosis Risk Assessment Survival Analysis Treatment Outcome Urinary Bladder Neoplasms/mortality/pathology/*therapy Bcg Bladder cancer Immunotherapy Personalized therapy Response prediction

Epirubicin/*therapeutic use Female Humans Immunotherapy/*methods Male Mitomycin/*therapeutic use *Mycobacterium bovis Urinary Bladder Neoplasms/immunology/pathology/*therapy Bacillus Calmette–Guérin Consistency Epirubicin Gemcitabine Heterogeneity Interferon-Alpha Intravesical instillation therapies Mitomycin C Pairwise/network meta-analysis Tumor progression Tumor recurrence

Antineoplastic Agents/*therapeutic use Carcinoma Transitional Cell/pathology/*therapy Chemotherapy Adjuvant Cystectomy Cystoscopy Humans Lymph Node Excision Muscle Smooth/*pathology *Neoadjuvant Therapy Neoplasm Invasiveness *Organ Sparing Treatments Progression-Free Survival Proportional Hazards Models *Radiotherapy Adjuvant Survival Rate Urinary Bladder Neoplasms/pathology/*therapy Bladder preserving Cancer Muscle invasive Radical cystectomy Trimodal